Steroid-Sparing Topicals: Calcineurin Inhibitors and PDE4

The problem these drugs were built to solve

Topical steroids work — until the skin itself becomes the side effect. As covered in the Topical Corticosteroids chapter, steroids suppress inflammation broadly and powerfully, but chronic use — especially on thin or occluded skin — produces atrophy: the epidermis and dermis literally thin, collagen breaks down, telangiectasias appear, striae form, and the skin can become fragile and steroid-dependent. The face, eyelids, and flexures (the folds of the neck, axillae, and groin) are exactly where skin is thinnest and where these changes come fastest. And atopic dermatitis, seborrhoeic dermatitis, and many facial or genital dermatoses are chronic — they need months or years of control, not a two-week burst. Put those two facts together and you have a genuine clinical dilemma: the diseases that most need long-term topical anti-inflammatories are the ones where long-term steroids do the most harm. The steroid-sparing topicals exist precisely to break that bind.

Topical calcineurin inhibitors: how they work

They interrupt the T cell at the exact step that turns on inflammation. The two topical calcineurin inhibitors (TCIs) are tacrolimus (marketed as Protopic, an ointment) and pimecrolimus (marketed as Elidel, a cream). Both are macrolactams, and both hit the same intracellular target. Inside an activated T cell, the drug binds an immunophilin called FKBP (FK-binding protein). That drug–FKBP complex then inhibits calcineurin, the calcium-dependent phosphatase whose job is to dephosphorylate the transcription factor NFAT. Blocked, NFAT can no longer enter the nucleus, so it cannot switch on the genes for pro-inflammatory cytokines — interleukin-2 and the other T-cell signals that drive the eczematous inflammatory cascade. In one line: FKBP → inhibit calcineurin → block NFAT → less T-cell cytokine transcription. This is the same molecular target as systemic ciclosporin and oral tacrolimus, taught in full in the Inflammation section — but applied to the skin surface, it acts locally and spares the whole body.

Where the calcineurin inhibitors shine

Because they do not cause atrophy, TCIs are the go-to for the sites steroids fear: the face, the eyelids and periorbital skin, the lips, and the flexural and genital areas. They are second-line therapy in atopic dermatitis (eczema, covered in depth in the Eczema chapter) — reached for when steroids are failing, poorly tolerated, or simply cannot be used long enough at a sensitive site. Tacrolimus is the more potent of the two and is used for moderate-to-severe disease; pimecrolimus is milder and favoured for mild-to-moderate disease and very delicate skin. Beyond eczema they are genuinely useful off the beaten track: seborrhoeic dermatitis of the face, vitiligo (especially facial), oral and genital lichen planus, and the erythema of rosacea and perioral dermatitis, where a steroid would make things worse. Their defining virtue is stated simply: unlimited-duration control on skin that steroids would eventually ruin.

The boxed warning that didn't hold up

When TCIs launched, regulators issued a black-box (boxed) warning raising a theoretical risk of skin cancer and lymphoma — reasoning by analogy from systemic transplant immunosuppression, where whole-body calcineurin blockade does raise malignancy risk. It was a cautious extrapolation, not a finding. Two decades of registry data, large cohort studies, and long-term follow-up have since failed to show any real increase in cancer from topical use. The reason is pharmacological: applied to skin, these large molecules achieve only minimal, transient systemic absorption — nothing close to the sustained whole-body immunosuppression a transplant patient lives with. The warning is now widely regarded as unsupported, and dermatology guidelines treat TCIs as safe for long-term use. Some patients will still have read the old warning online; the honest counsel is that the concern was theoretical and has not materialised in real-world data.

Proactive therapy: treating the calm, not just the storm

The best use of a steroid-sparing drug is on skin that already looks healed. Because TCIs are safe on skin over the long term, they enabled a strategy steroids never could: proactive, or maintenance, therapy — often called weekend therapy. Instead of only treating a flare and stopping, the patient applies the drug two or three times a week to the sites that repeatedly flare, even while they look clear. Subclinical inflammation smoulders in atopic skin between visible flares; damping it pre-emptively means fewer flares, longer remissions, and less total drug over the year. You could not do this with a potent steroid — twice-weekly indefinite steroid on the same spot is a recipe for atrophy — but with a non-atrophying agent it is both safe and, in trials, clearly effective. It is the topical embodiment of a principle from the Inflammation section: control the disease in its quiet phase, not just its loud one.

Topical PDE4 inhibitors: a second steroid-free route

Raise cAMP inside the inflammatory cell and it calms down on its own. The newer steroid-sparing class works one messenger further downstream. Phosphodiesterase-4 (PDE4) is the enzyme that breaks down cyclic AMP (cAMP) inside immune and inflammatory cells. cAMP is an intracellular "calm-down" signal: when it is high, the cell dials back its output of pro-inflammatory cytokines. Inhibit PDE4 and cAMP is no longer degraded, so it accumulates — and the cell throttles down TNF-α, interleukins, and other inflammatory mediators. In one line: block PDE4 → cAMP rises → fewer pro-inflammatory cytokines. The topical agents are crisaborole (Eucrisa, an ointment) for atopic dermatitis, and topical roflumilast (a cream) for psoriasis and seborrhoeic dermatitis. This is the same target as oral apremilast, the systemic PDE4 inhibitor used for psoriasis and psoriatic arthritis in the Inflammation section — again, brought to the skin surface to act locally without systemic exposure.

Crisaborole is indicated for mild-to-moderate atopic dermatitis, and like the TCIs it does not thin skin, so it too suits the face and folds and long-term use. Topical roflumilast has broadened the class into plaque psoriasis — including notoriously tricky intertriginous (skin-fold) psoriasis, where steroids atrophy and where a non-steroid is a real advance — and into seborrhoeic dermatitis. The characteristic adverse effect is, once again, application-site burning or stinging, generally mild. As a class the PDE4 inhibitors sit alongside the TCIs as the second family of non-steroid topical anti-inflammatories: different target, same clinical promise of controlling inflammation without the atrophy tax.

Where they sit relative to steroids

Steroid-sparing does not mean steroid-replacing. For most acute flares a topical steroid is still faster, stronger, and far cheaper — it remains first-line, and these agents are chosen when the site or the duration makes a steroid unwise. The decision framework is practical: on thin or sensitive skin (face, eyelids, genitals, flexures), or when a patient needs continuous long-term control, or when steroid atrophy has already begun, reach for a TCI or a topical PDE4 inhibitor. The honest downsides are two: the transient application-site burning, and a substantially higher cost than a generic steroid. Looking forward, these two classes are no longer alone — the topical JAK inhibitors (such as ruxolitinib cream), covered in their own chapter, are the next steroid-sparing wave, adding a third non-atrophying mechanism to the same shelf. Together they mean that "the skin is too thin for a steroid" is no longer the dead end it once was.